Skip to main content

Table 1 Comparison of antihypertensive drug users and non-users by implants (n=377)

From: Impact of renin-angiotensin system inhibitors and beta-blockers on dental implant stability

Variable All
n
Antihypertensive drug OR (95% CI) P
Users n (%) Non-users n (%)
Gender
 Female 179 23 (50.0) 156 (47.1) 1  
 Male 198 23 (50.0) 175 (52.9) 0.89 (0.46–1.74) ns
Age
 <70 207 17 (37.0) 190 (57.4) 1  
 ≥70 170 29 (63.0) 141 (42.6) 2.30 (1.17–4.64) 0.01*
Implant system
 STR 289 30 (65.2) 259 (78.3) 1  
 SPI 88 16 (34.8) 72 (21.8) 1.92 (0.92–3.86) ns
Implant diameter
 4.1 mm 187 20 (43.5) 167 (50.5) 1  
 < 4.1 mm 63 3 (6.5) 60 (18.1) 0.42 (0.08–1.49) ns
 > 4.1 mm 127 23 (50.0) 104 (31.4) 1.85 (0.92–3.73) ns
Implant length
 <11 mm 169 25 (54.4) 144 (43.5) 1  
 ≥11 mm 208 21 (45.7) 187 (56.5) 0.65 (0.33–1.26) ns
Localization
 Maxillary 225 23 (50.0) 202 (61.0) 1  
 Mandibular 152 23 (50.0) 129 (39.0) 1.57 (0.80–3.05) ns
Healing time
 < 14 weeks 162 20 (43.5) 142 (42.9) 1  
 > 14 weeks 215 26 (56.5) 189 (57.1) 0.98 (0.50–1.93) ns
Bone situation/implant technique
 Fully ossified situation 305 38 (82.6) 267 (80.7) 1  
 Immediate insertion 41 3 (6.5) 38 (11.5) 0.56 (0.11–1.89) ns
 Internal sinus elevation (immediate insertion)a 9 0 (0.0) 9 (2.72) - -
 One-step/two-step insertion after internal sinus elevation 22 5 (10.87) 17 (5.14) 2.07 (0.56–6.27) ns
  1. STR Straumann implants, SPI Thommen implants, p p-value, OR odds ratio, 95% CI 95% confidence interval, *indicate significance, p p-value, ns not significant
  2. aCalculating the odds ratio with its confidence interval for the zero-cell counts via mathematical correction (Haldane-Anscombe correction) was not necessary, as this group did not contain any antihypertensive drug users